AB07002: A 96-Week, Prospective, Multicenter, Randomised, Double-Blind, Placebo-Controlled, 2-Parallel Group, Phase 3 Study to Compare Efficacy and Safety of Masitinib 6 mg/kg/Day/ Versus Placebo

  • Berger, Joseph (PI)

Grants and Contracts Details

StatusFinished
Effective start/end date3/1/113/31/15